An NCI-designated Comprehensive Cancer Center
By City of Hope | October 30, 2018
Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. A new City of Hope chimeric antigen receptor (CAR) T cell trial — the first to focus on HER2-postive breast cancer patients with brain metastases — is now enrolling potential participants.
CAR T cell immunotherapy is being actively investigated for the treatment of solid tumors, including HER2+ cancers. City of Hope’s Saul Priceman, Ph.D., and colleagues have designed CAR molecules and a novel route of CAR T cell administration that are now being tested in patients with HER2+ breast cancer that has metastasized to the brain.
HER2-CAR constructs that contained either CD28 or 4-1BB intracellular costimulatory signaling domains were compared based on a variety of endpoints. Additionally, HER2-CAR T cells delivered by intravenous, local intratumoral or regional intraventricular routes of administration using in vivo human xenograft models of breast cancer that had metastasized to the brain were evaluated.
The preclinical study results showed that the 4-1BB intracellular costimulatory signaling domains improved tumor targeting with reduced T cell exhaustion phenotype. The study also found that regional intraventricular delivery of HER2-CAR T cells demonstrated robust anti-tumor efficacy.
The phase 1 trial now enrolling at City of Hope will evaluate the safety and effectiveness of this CAR T cell therapy for these patients, who have tried other types of treatment that are no longer effective.
For enrollment information in this study, please contact Fatemeh Bidmeshki, R.N., by phone at 626-218-3939.
For all other CAR T inquiries (patient, physician, clinical trials) contact our dedicated CAR T referral line to speak directly with a nurse navigator at 833-310-CART (2278).

Subscribe to Physician News for the latest developments in diabetes and cancer prevention, treatment, research, clinical trials and upcoming continuing medical education (CME) programs.
We will always respect your privacy and you may unsubscribe at any time. We will never sell or exchange your information with others. View our complete Privacy Policy .

*Required Fields